# Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

> clinical trial · VERIFIED · 2026-06-29

Status: NOT_YET_RECRUITING · Sponsor: Faron Pharmaceuticals Ltd · Condition: Higher Risk Myelodysplastic Syndromes

- Company: Faron Pharmaceuticals Ltd
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07672769

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.